Spondyloarthritis & psoriatic arthritis

Effect of gender and age on bDMARD efficacy for axial spondyloarthritis patients: a meta-analysis of randomized controlled trials

Rheumatology (Oxford)Published Systematic review and meta-analysis of randomised trials

Authors' conclusion

The bDMARDs were efficacious in all axSpA patients regardless of gender or age. However, the treatment responses were more evident in male and younger patients. Also, females with r-axSpA had greater responses than those with nr-axSpA, whereas no relevant difference was observed in males, indicating that the gender difference on efficacy was greater in nr-axSpA patients.

Study context

Population
Patients with axial SpA (axSpA) in RCTs of b/tsDMARDs (PubMed, Scopus, Embase, before 10 August 2023)
Participants
4,127 patients9 studies
Comparison
bDMARDs vs placebo, by gender and age
Outcome
ASAS40 response
Methodological detailssubgroup analysis, Only one tsDMARD study met inclusion criteria and was excluded from further analysis
  • Subgroup analysis
  • Only one tsDMARD study met inclusion criteria and was excluded from further analysis

Pooled result

As reported in the abstract

ASAS40 response, bDMARDs vs placebo, by gender and age subgroup
bDMARDs vs PlaceboOdds ratio (95% CI)
Males
3.14(2.66–3.70)
Females
2.32(1.82–2.82)
Younger
4.00(2.50–6.40)
Older
2.21(1.15–4.22)

OR

Efficacy more evident in males
1.89 (95% CI 1.56, 2.30)
Efficacy more evident in younger patients
2.07 (95% CI 1.42, 3.02)

Further pooled results

Gender difference in efficacy by axSpA subtype (subgroup)

Gender difference in efficacy more obvious in nr-axSpA
P for heterogeneity = 0.03, I2 = 78.1%
Males with r-axSpA and nr-axSpA shared similar responses
P for heterogeneity = 0.87, I2 = 0%
Females with r-axSpA showed greater response than those with nr-axSpA
P for heterogeneity = 0.005, I2 = 87.4%

Original publication

Effect of gender and age on bDMARD efficacy for axial spondyloarthritis patients: a meta-analysis of randomized controlled trials. Rheumatology (Oxford). Published 6 February 2024. doi:10.1093/rheumatology/keae088

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.